US Stock MarketDetailed Quotes
ARPO Aerpio Pharmaceuticals
- 0.000
- 0.0000.00%
Close Apr 26 09:30 ET
0Market Cap0.00P/E (TTM)
0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)20.87MShares34.50052wk High0.00P/B0Float Cap31.65052wk Low--Dividend TTM1.71MShs Float65.250Historical High--Div YieldTTM0.00%Amplitude6.300Historical Low--Avg Price1Lot Size
About Aerpio Pharmaceuticals Company
Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.
Company Profile
SymbolARPO
Company NameAerpio Pharmaceuticals
CEODr. Joseph Gardner, PhD
MarketNASDAQ
Employees12
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Websitehttps://www.aerpio.com
Company Executives
- Name
- Position
- Salary
- Dr. Joseph Gardner, PhD
- Director, President and Principal Executive Officer
- 800.82K
- Regina Marek
- Vice President of Finance, Principal Financial and Accounting Officer
- 476.18K
- Steven Prelack
- Chairman of the Board
- 102.59K
- Anupam Dalal
- Independent Director
- 84.67K
- Pravin Dugel
- Independent Director
- 76.48K
- Cheryl L. Cohen
- Independent Director
- 88.29K
- Dr. Caley Castelein, M.D.
- Independent Director
- 84.76K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg